What's Happening?
Anixa Biosciences has announced updated positive survival data from its Phase 1 trial of liraltagene autoleucel (lira-cel), a CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) for recurrent ovarian cancer. The trial, presented at the International
Society for Cell & Gene Therapy 2026 Annual Meeting, showed that several patients survived significantly beyond the expected median survival. Notably, one patient survived 28 months post-treatment. The trial has not encountered dose-limiting toxicities, and no significant adverse events related to lira-cel have been observed.
Why It's Important?
The promising survival data from Anixa's trial could represent a breakthrough in the treatment of recurrent ovarian cancer, a condition with limited options and poor prognosis. The therapy's favorable safety profile and potential efficacy may offer new hope for patients and could influence future treatment protocols. This development is significant for the biotechnology sector, as it highlights the potential of CAR-T therapies in oncology, potentially leading to increased investment and research in this area.
What's Next?
Anixa plans to continue dose escalation in the trial, with the next cohort receiving a higher dose and additional lymphodepletion treatment. The company aims to further evaluate the therapy's safety and efficacy, which could lead to expanded clinical trials or regulatory submissions. The biotechnology community and investors will be watching closely, as successful outcomes could lead to new partnerships and commercialization opportunities.
